Agile Therapeutics, a US-based company making a contraceptive patch for women, has raised $40m in its series C round from a consortium including Kaiser Permanente Ventures, the corporate venturing unit of the US’s largest health care system.
Alongside Kaiser Permanente in the C round are venture capital firms Aisling Capital, which led the round, Care Capital, Investor Growth Capital, ProQuest Investments and Novitas Capital.
Agile is preparing for commercialization of its lead product, AG200-15, a once-weekly, low-dose contraceptive patch having filed a New Drug Application with the US Food and Drug Administration for AG200-15 and anticipates a response in the first quarter of 2013.
In June 2010, Agile raised $45m in its series B round for Agile before Al Altomari joined as executive president later that year.